Facts:

• United American Pharmaceuticals, Inc. filed a petition for the trademark "BIOFERIN" on October 21, 1957.
• The trademark was first used in the Philippines on August 13, 1957, for a medicinal preparation serving as an antihistamine, analgesic, and antipyretic, enriched with vitamin C and Bioflavonoid.
• The product is intended for treating common colds, influenza, and febrile diseases with capillary hemorrhagic tendencies, classified under Class 6 for "Medicines and Pharmaceutical Preparations."
• Bristol Myers Company opposed the application on January 6, 1959, claiming rights over the trademark "BUFFERIN," registered in the Philippines since March 3, 1954, and in the U.S. since November 4, 1952.
• "BUFFERIN" is categorized as an antacid analgesic for relief from headaches, colds, and minor aches, first used in the Philippines on May 13, 1953.
• Bristol Myers argued that "BIOFERIN" would infringe its rights and mislead the public due to similarities in spelling, pronunciation, and design.
• On January 18, 1961, both parties submitted a joint petition to resolve the issue through memoranda.
• The Director of Patents ruled in favor of United American Pharmaceuticals on June 21, 1963, stating the trademarks were not confusingly similar.
• Bristol Myers appealed this decision to the Supreme Court on July 24, 1963.

Issue:

• (Unlock)

Ruling:

• The Supreme Court affirmed the Director of Patents' decision, ruling that "BIOFERIN" and "BU...(Unlock)

Ratio:

• The Supreme Court emphasized that the assessment of confusing similarity should not be limited to spelling and pronunciation but should consider the overall presentation of the trademarks on their labels and the context of the goods.
• The Court referenced the case of Mead Johnson & Co. vs. N.V.J.Van Dorp, Ltd., highlighting the importance of a comprehensive evaluation of trademarks.
• Significant differences were noted between "BIOFERIN" and "BUF...continue reading